Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
Verrica Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, expectations were $-0.47. Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. (VRCA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 7,099,182 | $51,966,012 | +41% | 1.15% |
| 2. | VenBio Select Advisor Kurt Von Emster | 3,999,999 | $29,279,993 | +36% | 0.4% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 65,305 | $478,033 | 0% | |
| 4. | AQR Capital Management Cliff Asness | 22,358 | $163,661 | +2% | 0% |
| 5. | 15,400 | $112,728 | +1184% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.24 | 115,774 | Large Shareholder | 7,099,182 | 2023-12-29 | Filing | |
| $7.08 | 126,116 | Large Shareholder | 6,983,408 | 2023-12-28 | Filing | |
| $7.20 | 79,726 | Large Shareholder | 6,857,292 | 2023-12-27 | Filing | |
| $6.49 | 54,652 | Large Shareholder | 6,777,566 | 2023-12-26 | Filing | |
| $6.67 | 250,000 | Large Shareholder | 6,722,914 | 2023-12-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.97 | 11,266 | Officer | 92,392 | 2023-11-15 | Filing | |
| $2.93 | 21,580 | Officer | 103,658 | 2023-11-14 | Filing | |
| $2.97 | 3,036 | Officer | 86,257 | 2023-11-15 | Filing | |
| $2.93 | 5,817 | Officer | 89,293 | 2023-11-14 | Filing | |
| $2.97 | 9,632 | Officer | 34,416 | 2023-11-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,509,063 | $11,046,341 | 0% | |
| 2. | 1,261,101 | $9,231,259 | 0% | |
| 3. | 1,135,743 | $8,313,639 | 0% | |
| 4. | 429,677 | $3,145,585 | 0% | |
| 5. | 389,267 | $2,849,434 | 0% |
News See All
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call.
Hedge Fund and Insider Trading News: Paul Marshall, Crispin Odey, Point72 Asset Management, Asgard Fixed Income Fund, Brookfield Hedge Solutions Advisors, B Riley Financial Inc (RILY), Verrica Pharmaceuticals Inc. (VRCA), and More
GB News owner Sir Paul Marshall’s hedge fund has made a multi-million pound gain on its bet against NatWest shares following the exit of Dame Alison Rose.
12 Most Promising Micro-Cap Stocks According to Analysts
In this article, we will take a look at the 12 most promising micro-cap stocks according to analysts.
Hedge Fund and Insider Trading News: Andreas Halvorsen, Ken Griffin, Bill Ackman, Michael Burry, Welton Investment Partners, CalAmp Corp. (CAMP), Keurig Dr Pepper Inc (KDP), and More
It’s hard to escape Ken Griffin’s name if you live in Chicago.
5 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman
In this article, we discuss the 5 best pharmaceutical stocks to buy according to billionaire Joseph Edelman.
Here is What Hedge Funds Think About Verrica Pharmaceuticals Inc. (VRCA)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Hedge Funds Never Been Less Bullish On Verrica Pharmaceuticals Inc. (VRCA)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Is Verrica Pharmaceuticals Inc. (VRCA) A Good Stock To Buy?
Does Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company.
Hedge Fund and Insider Trading News: Steve Cohen, Crispin Odey, Jana Partners, Verrica Pharmaceuticals Inc (VRCA), Easterly Acquisition Corp (EACQ), Progressive Corp (PGR), and More
Billionaire Steve Cohen sees the U.S. economy slowing and predicted a bear market is coming as early as 18 months from now, according to a report by the Financial Times on Wednesday.